| [1] |
Bailey P, Cushing H. Medulloblastoma cerebelli: a common type of midcerebellar glioma of childhood[J]. Arch Neurol Psychiatry, 1925, 14(2): 192-224.
|
| [2] |
Wells EM, Khademian ZP, Walsh KS, et al. Postoperative cerebellar mutism syndrome following treatment of medulloblastoma: Neuroradiographic features and origin[J]. J Neurosurg Pediatr, 2010, 5(4): 329-334.
|
| [3] |
Michiels EM, Weiss MM, Hoovers JM, et al. Genetic alterations in childhood medulloblastoma analyzed by comparative genomic hybridization[J]. J Pediatr Hematol Oncol, 2002, 24(3): 205-210.
|
| [4] |
Rutkowski S, von Hoff K, Emser A, et al. Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis[J]. J Clin Oncol, 2010, 28(33): 4961-4968.
|
| [5] |
Chang CH, Housepian EM, Herbert C Jr. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas[J]. Radiology, 1969, 93(6): 1351-1359.
|
| [6] |
Khatua S, Song A, Citla Sridhar D, et al. Childhood medulloblastoma: current therapies, emerging molecular landscape and newer therapeutic insights[J]. Curr Neuropharmacol, 2018, 16(7): 1045-1058.
|
| [7] |
Kool M, Korshunov A, Remke M, et al. Molecular subgroups of medulloblastoma: an international metaanalysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, group 3, and group 4 medulloblastomas[J]. Acta Neuropathol, 2012, 123(4): 473-484.
|
| [8] |
Küchler J, Hartmann W, Waha A, et al. p75(NTR) induces apoptosis in medulloblastoma cells[J]. Int J Cancer, 2011, 128(8): 1804-1812.
|
| [9] |
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary[J]. Acta Neuropathol, 2016, 131(6): 803-820.
|
| [10] |
Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants[J]. J Clin Oncol, 2011, 29(11):1408-1414.
|
| [11] |
Tabori U, Baskin B, Shago M, et al. Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations[J]. J Clin Oncol, 2010, 28(8): 1345-1350.
|
| [12] |
Pietsch T, Schmidt R, Remke M, et al. Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort[J]. Acta Neuropathol, 2014, 128(1): 137-149.
|
| [13] |
Shih DJ, Northcott PA, Remke M, et al. Cytogenetic prognostication within medulloblastoma subgroups[J]. J Clin Oncol, 2014, 32(9): 886-896.
|
| [14] |
Boulay G, Awad ME, Riggi N, et al. OTX2 activity at distal regulatory elements shapes the chromatin landscape of group 3 medulloblastoma[J]. Cancer Discov, 2017, 7(3): 288-301.
|
| [15] |
Skowron P, Ramaswamy V, Taylor MD. Genetic and molecular alterations across medulloblastoma subgroups[J]. J Mol Med (Berl), 2015, 93(10): 1075-1084.
|
| [16] |
Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (st Jude medulloblastoma-96): long-term results from a prospective, multicentre trial[J]. Lancet Oncol, 2006, 7(10): 813-820.
|
| [17] |
Ellison DW, Kocak M, Dalton J, et al. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables[J]. J Clin Oncol, 2011, 29(11): 1400-1407.
|
| [18] |
Thompson EM, Hielscher T, Bouffet E, et al. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis[J]. Lancet Oncol, 2016, 17(4): 484-495.
|
| [19] |
Tarbell NJ, Friedman H, Polkinghorn WR, et al. High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031)[J]. J Clin Oncol, 2013, 31(23): 2936-2941.
|
| [20] |
Gandola L, Massimino M, Cefalo G, et al. Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma[J]. J Clin Oncol, 2009, 27(4): 566-571.
|